Cohance Lifesciences Ltd (COHANCE)
🎯 Key Takeaways
- Revenue declined 31.8% QoQ to ₹422 in Q1FY27.
- Market Cap
- ₹17,474
- P/E Ratio
- 298.5
- P/B Ratio
- 4.47
- ROE
- 2.7%
- ROCE
- 3.3%
- Debt/Equity
- 0.04
- Promoter
- 57.5%
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 556 | 545 | 619 | 422 |
| Operating Profit | 77 | 48 | 47 | -48 |
| OPM % | 13.8% | 8.9% | 7.7% | -11.5% |
| Net Profit | 66 | 29 | 8 | -45 |
| EPS | ₹1.94 | ₹0.96 | ₹0.51 | ₹-0.63 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 25 | 25 | 38 | 38 |
| Reserves | 3,623 | 1,953 | 3,873 | 3,749 |
| Borrowings | 486 | 39 | 170 | 451 |
| Total Liabilities | 5,481 | 2,506 | 5,730 | 5,568 |
| Fixed Assets | 1,765 | 652 | 3,373 | 1,763 |
| Investments | 337 | 751 | 529 | 454 |
| Total Assets | 5,481 | 2,506 | 5,730 | 5,568 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating | +288 | +368 |
| Investing | -255 | -255 |
| Financing | +3 | -165 |
| Net Cash Flow | +36 | -51 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 57.5% | 57.5% | 57.5% | 57.5% |
| FII | 6.5% | 6.0% | 5.6% | 6.5% |
| DII | 20.8% | 21.6% | 21.8% | 20.1% |
| Public | 6.4% | 6.8% | 7.0% | 7.7% |
| # Shareholders | 75,284 | 81,877 | 85,230 | 99,149 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.46 L Cr | 36.9 | 18.7% | — | 0.05 |
| DIVISLAB | 2.52 L Cr | 86.0 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.87 L Cr | 78.4 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.19 L Cr | 26.6 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.1 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 98.0 | 20.8% | — | 0.45 |
| MANKIND | 1.05 L Cr | 51.4 | 13.9% | — | 0.38 |
| DRREDDY | 1.04 L Cr | 32.3 | 10.1% | — | 0.17 |
| AUROPHARMA | 97,987 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,190 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- Announcement2026-09-28Cohance Lifesciences Ltd announced that its trading window closes on 1 October 2026 for insiders and stays shut until 48 hours after the unaudited fin…
- Announcement2026-09-21Cohance Lifesciences announced that the USFDA inspected its API facility in Andhra Pradesh from September 14-19, 2026, issuing five Form 483 observati…
- 🟡 Board Meeting2026-09-18Cohance Lifesciences invested USD 10 million in newly issued Compulsorily Convertible Preferred Stock (CCPS) of its subsidiary NJ Bio Inc., USA, compl…
- 🔴 Announcement2026-09-17Cohance Lifesciences Ltd announced it will attend the JP Morgan India Conference in Mumbai on 22 September 2026 and a JP Morgan Roadshow in Hyderabad …
- 🟡 Board Meeting2026-09-17Cohance Lifesciences held its 8th Annual General Meeting on 17 September 2026 via video conference, approving standalone and consolidated financial st…
- 🟡 voting results2026-09-17Cohance Lifesciences held its 8th Annual General Meeting on 17 September 2026 via video conference, approving standalone and consolidated financial st…
- 🔴 Announcement2026-09-05Cohance Lifesciences announced that the USFDA completed an inspection of its formulation plant in Shamshabad, Telangana, from 27 August to 4 September…
- 🟡 Board Meeting2026-09-03Cohance Lifesciences announced a strategic reorganisation involving two key transactions: acquiring an additional 244,587 shares in its subsidiary NJ …
- 🔴 Announcement2026-09-03Cohance Lifesciences announced two strategic transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: a USD 13 million additional invest…
- 🔴 Announcement2026-08-27Cohance Lifesciences Ltd announced it will attend the Ashwamedh - Elara India Dialogue 2026 conference on September 1, 2026 in Mumbai, featuring group…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when COHANCE files new disclosures
Track COHANCE filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track COHANCE — FreeFree account · 2 AI queries/day